Curated News
By: NewsRamp Editorial Staff
April 29, 2026

VolitionRx Achieves Milestone with Finger-Prick Sepsis Detection Prototype

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • VolitionRx's lateral flow prototype enables early sepsis detection at point of care, expanding market reach and partnership opportunities.
  • The prototype detects nucleosomes in capillary blood via lateral flow, building on venous blood correlation with Nu.Q assay.
  • This innovation could save lives by enabling early sepsis detection in underserved regions with limited lab access.
  • A finger-prick test for sepsis detection could transform emergency care, making critical diagnosis as simple as a glucose test.

Impact - Why it Matters

This news matters because sepsis is a life-threatening condition that requires rapid detection and treatment. VolitionRx's finger-prick prototype could enable early diagnosis in remote or resource-limited settings, potentially saving countless lives by catching sepsis before it becomes critical. The ability to test at point-of-care without lab infrastructure democratizes access to advanced diagnostics, which is crucial for improving global health outcomes.

Summary

VolitionRx Limited (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, has announced a significant technical milestone in the fight against sepsis. The company successfully detected nucleosomes in capillary blood from critically ill patients using a lateral flow finger-prick prototype. This study, conducted as part of the SUMMIT program, demonstrates the feasibility of early detection of immune disruptions associated with conditions like sepsis, even in point-of-care and non-laboratory settings. The prototype builds on prior results showing a strong correlation between venous blood samples tested with Volition's lateral flow system and its established Nu.Q nucleosome assay. By expanding access to testing through point-of-care use, Volition aims to broaden its addressable market and support future commercialization efforts, including potential partnerships to increase access in regions with limited laboratory infrastructure.

The company emphasized that this approach could revolutionize sepsis detection, making it more accessible and faster, which is critical given that sepsis is a leading cause of death worldwide. The lateral flow prototype is designed to be simple, easy to use, and cost-effective, aligning with Volition's mission to save lives and improve outcomes for people and animals with life-altering diseases through earlier detection and monitoring. Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For more details, visit the full press release at https://ibn.fm/ioEmu.

Volition is dedicated to advancing the science of epigenetics and is developing and commercializing blood tests to detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company’s innovative work, as highlighted in this release, underscores its commitment to earlier detection and monitoring, which has the potential not only to prolong life but also to improve quality of life. Media enquiries can be directed to Louise Batchelor at mediarelations@volition.com. For further information, visit the company’s website at www.Volition.com.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VolitionRx Achieves Milestone with Finger-Prick Sepsis Detection Prototype

blockchain registration record for this content.